Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Short-term Investments (2016 - 2025)

ImmunityBio (IBRX) has disclosed Short-term Investments for 11 consecutive years, with $154.5 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 2321.0% to $154.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $154.5 million through Dec 2025, up 2321.0% year-over-year, with the annual reading at $154.5 million for FY2025, 2321.0% up from the prior year.
  • Short-term Investments for Q4 2025 was $154.5 million at ImmunityBio, down from $197.6 million in the prior quarter.
  • The five-year high for Short-term Investments was $197.6 million in Q3 2025, with the low at $931000.0 in Q1 2025.
  • Average Short-term Investments over 5 years is $46.7 million, with a median of $17.2 million recorded in 2024.
  • The sharpest move saw Short-term Investments crashed 98.21% in 2023, then soared 3489.67% in 2024.
  • Over 5 years, Short-term Investments stood at $136.0 million in 2021, then plummeted by 98.13% to $2.5 million in 2022, then crashed by 60.32% to $1.0 million in 2023, then soared by 532.41% to $6.4 million in 2024, then soared by 2321.0% to $154.5 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $154.5 million, $197.6 million, and $16.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.